JSJoshua A. Sommers

Joshua A. Sommers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua A. Sommers has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Robert M. Brosh

    Helicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, USA

    6 shared publications
  • Claudia M. Nicolae

    Department of Molecular and Precision Medicine, The Pennsylvania State University College of Medicine , Hershey, PA 17033

    2 shared publications
  • George-Lucian Moldovan

    Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, USA

    2 shared publications
  • Sanket Awate

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, USA

    2 shared publications
  • Tomasz Kulikowicz

    Helicases and Genomic Integrity Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Research Center, Baltimore, Maryland, USA

    2 shared publications
  • Abdulsalam Abu-Libdeh

    Department of Pediatrics, Division of Pediatric Endocrinology, Makassed Hospital and Al-Quds Medical School, Jerusalem, Palestinian Territory, Occupied

    1 shared publication

Latest Publications

  • Open Access

    SARS-CoV-2 Nsp13 helicase resolves G-quadruplexes and is inhibited by G4 ligands or an antiviral regulator: Implications for G4 anti-coronavirus therapies

    by Joe C. George, Tomasz Kulikowicz, Pierce T. Bombard, Martina Rossi, Adaira J. Dumm, Olivia M. Anderson, Joshua A. Sommers, Robert M. Brosh

  • Open Access

    Biochemical analysis of DNA synthesis blockage by G-quadruplex structure and bypass facilitated by a G4-resolving helicase

    by Joshua A. Sommers, Katrina N. Estep, Robert W. Maul, Robert M. Brosh


  • Open Access

    RECON syndrome is a genome instability disorder caused by mutations in the DNA helicase RECQL1

    by Bassam Abu-Libdeh, Satpal S. Jhujh, Srijita Dhar, Joshua A. Sommers, Arindam Datta, Gabriel M.C. Longo, Laura J. Grange, John J. Reynolds, Sophie L. Cooke, Gavin S. McNee, et al.

    Despite being the first homolog of the bacterial RecQ helicase to be identified in humans, the function of RECQL1 remains poorly characterized. Furthermore, unlike other members of the human RECQ family of helicases, mutations in RECQL1 have not been associated with a genetic disease. Here, we identify 2 families with a genome instability disorder that we have named RECON (RECql ONe) syndrome, caused by biallelic mutations in the RECQL gene. The affected individuals had short stature, progeroid facial features, a hypoplastic nose, xeroderma, and skin photosensitivity and were homozygous for the same missense mutation in RECQL1 (p.Ala459Ser), located within its zinc binding domain. Biochemical analysis of the mutant RECQL1 protein revealed that the p.A459S missense mutation compromised its ATPase, helicase, and fork restoration activity, while its capacity to promote single-strand DNA annealing was largely unaffected. At the cellular level, this mutation in RECQL1 gave rise to a defect in the ability to repair DNA damage induced by exposure to topoisomerase poisons and a failure of DNA replication to progress efficiently in the presence of abortive topoisomerase lesions. Taken together, RECQL1 is the fourth member of the RecQ family of helicases to be associated with a human genome instability disorder.


  • Open Access

    WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells

    by Arindam Datta, Kajal Biswas, Joshua A. Sommers, Haley Thompson, Sanket Awate, Claudia M. Nicolae, Tanay Thakar, George-Lucian Moldovan, Robert H. Shoemaker, Shyam K. Sharan, et al.

    The tumor suppressor BRCA2 protects stalled forks from degradation to maintain genome stability. However, the molecular mechanism(s) whereby unprotected forks are stabilized remains to be fully characterized. Here, we demonstrate that WRN helicase ensures efficient restart and limits excessive degradation of stalled forks in BRCA2-deficient cancer cells. In vitro, WRN ATPase/helicase catalyzes fork restoration and curtails MRE11 nuclease activity on regressed forks. We show that WRN helicase inhibitor traps WRN on chromatin leading to rapid fork stalling and nucleolytic degradation of unprotected forks by MRE11, resulting in MUS81-dependent double-strand breaks, elevated non-homologous end-joining and chromosomal instability. WRN helicase inhibition reduces viability of BRCA2-deficient cells and potentiates cytotoxicity of a poly (ADP)ribose polymerase (PARP) inhibitor. Furthermore, BRCA2-deficient xenograft tumors in mice exhibited increased DNA damage and growth inhibition when treated with WRN helicase inhibitor. This work provides mechanistic insight into stalled fork stabilization by WRN helicase when BRCA2 is deficient.


  • Open Access

    Cellular Assays to Study the Functional Importance of Human DNA Repair Helicases

    by Sanket Awate, Srijita Dhar, Joshua A. Sommers, Robert M. Brosh

    DNA helicases represent a specialized class of enzymes that play crucial roles in the DNA damage response. Using the energy of nucleoside triphosphate binding and hydrolysis, helicases behave as molecular motors capable of efficiently disrupting the many noncovalent hydrogen bonds that stabilize DNA molecules with secondary structure. In addition to their importance in DNA damage sensing and signaling, DNA helicases facilitate specific steps in DNA repair mechanisms that require polynucleotide tract unwinding or resolution. Because they play fundamental roles in the DNA damage response and DNA repair, defects in helicases disrupt cellular homeostasis. Thus, helicase deficiency or inhibition may result in reduced cell proliferation and survival, apoptosis, DNA damage induction, defective localization of repair proteins to sites of genomic DNA damage, chromosomal instability, and defective DNA repair pathways such as homologous recombination of double-strand breaks. In this chapter, we will describe step-by-step protocols to assay the functional importance of human DNA repair helicases in genome stability and cellular homeostasis. Key words Helicase DNA repair Genomic stability DNA damage Replication stress Genetic disease


  • Open Access

    A high-throughput screen to identify novel small molecule inhibitors of the Werner Syndrome Helicase-Nuclease (WRN)

    by Joshua A Sommers, Tomasz Kulikowicz, Deborah L Croteau, Thomas Dexheimer, Dorjbal Dorjsuren, Ajit Jadhav, David J Maloney, Anton Simeonov, Vilhelm A Bohr, Robert M Brosh

    Werner syndrome (WS), an autosomal recessive genetic disorder, displays accelerated clinical symptoms of aging leading to a mean lifespan less than 50 years. The WS helicase-nuclease (WRN) is involved in many important pathways including DNA replication, recombination and repair. Replicating cells are dependent on helicase activity, leading to the pursuit of human helicases as potential therapeutic targets for cancer treatment. Small molecule inhibitors of DNA helicases can be used to induce synthetic lethality, which attempts to target helicase-dependent compensatory DNA repair pathways in tumor cells that are already genetically deficient in a specific pathway of DNA repair. Alternatively, helicase inhibitors may be useful as tools to study the specialized roles of helicases in replication and DNA repair. In this study, approximately 350,000 small molecules were screened based on their ability to inhibit duplex DNA unwinding by a catalytically active WRN helicase domain fragment in a high-throughput fluorometric assay to discover new non-covalent small molecule inhibitors of the WRN helicase. Select compounds were screened to exclude ones that inhibited DNA unwinding by other helicases in the screen, bound non-specifically to DNA, acted as irreversible inhibitors, or possessed unfavorable chemical properties. Several compounds were tested for their ability to impair proliferation of cultured tumor cells. We observed that two of the newly identified WRN helicase inhibitors inhibited proliferation of cancer cells in a lineage-dependent manner. These studies represent the first high-throughput screen for WRN helicase inhibitors and the results have implications for anti-cancer strategies targeting WRN in different cancer cells and genetic backgrounds.